News

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023.

“Hundreds of organizations have been selected to join each network. Having been asked to become a member on both networks is a rare opportunity — SRI is honored,” said Kathlynn Brown, president of SRI’s Biosciences division.

Through these memberships, SRI gains access to potential funding and flexible contracting for faster award execution compared to traditional contract processes. This means that people can benefit from advanced healthcare innovations in discovery and treatment without having to wait for years.

The Customer Experience Hub seeks to make healthcare treatments accessible to everyone, from rural areas to cities. The Investor Catalyst Hub seeks to accelerate the broad commercialization of groundbreaking biomedical solutions. The networks utilize an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and minority-serving institutions, to deliver scalable positive healthcare outcomes for all Americans.

SRI delivers bioscience, applied research, and commercial transfer expertise — moving important health technologies from the research lab into the real world.

“SRI’s mission is to make an impact so people can live healthier and safer lives,” said Brown. “We’re proud to be a part of this nationwide health initiative to advance our innovations where they can make a difference. Our work in precision medicine is essential, but without government and commercial support, people, especially in rural and underserved areas, cannot benefit.”

SRI joins a nationwide network of organizations aligned to ARPA-H’s overarching mission of improving health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. ARPANET-H hubs and spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.

“The ARPA-H model is advantageous because the trusted members can move quickly, so the proper healthcare can be delivered faster and safer,” Brown said.

 

Learn more here.

Recent News

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …